Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer
- Conditions
- Pancreatic Cancer Stage IVPancreatic Cancer Stage IIIPancreas CancerPancreatic Cancer
- Registration Number
- NCT04137822
- Lead Sponsor
- Impatients N.V. trading as myTomorrows
- Brief Summary
An Expanded Access Program for IMM-101 for patients with advanced pancreatic cancer.
- Detailed Description
IMM-101 is a suspension of heat-killed whole cell Mycobacterium obuense. Since it is a heat-killed preparation, treatment is not associated with the potential side-effects of delivering live or attenuated organisms.
Five studies with IMM-101 have been completed including a 110-patient randomised Phase II study in pancreatic cancer and exploratory studies in other solid tumours (melanoma, colorectal cancer and advanced melanoma).
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
This Expanded Access Program is available for patients of 18 years or older with advanced pancreatic cancer for whom, in the opinion of their treating physician, other treatment options or clinical trials in this indication are unsuitable.
Female patient of child-bearing potential who is not, in the opinion of the physician, using an approved method of birth control (e.g., physical barrier [patient and partner], contraceptive pill or patch, spermicide and barrier, or intrauterine device [IUD]).
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
France
🇫🇷Paris, France
UK
🇬🇧London, United Kingdom